More recently, antibodies specifically targeting STn glycan have been reported and their conjugation with drugs led to the development of antibody-drug conjugates that demonstrated in vitro efficacy in STn-expressing cell lines and tumour growth inhibition in tumour xenograft cancer models36. This evidence concerns the gene EEF1A2 and cancer.